LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC) Rebrands as Argent BioPharma in Strategic Transformation
HempStreet, India's first research to retail medicinal cannabis venture, has launched 'ArtemiC,' a nutraceutical mouth spray to speed up recovery for patients with severe Covid-19 symptoms. ArtemiC has been launched in collaboration with MGC Pharma, a company with which HempStreet announced a partnership earlier this year. Headquartered in the UK, MGC Pharma is a pharmaceuticals company working on polyherbal formulations based on cannabis and other phytopharmaceuticals.
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has had a peer reviewed academic paper entitled 'The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling' published by MDPI.
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) and developer Caba Tech have launched ZAM, a data collection app with a machine learning algorithm.
MGC Pharmaceuticals said a patent had been granted, protecting its unique system used to deliver a cannabis-derived drug being developed to combat hard-to-treat forms of epilepsy, according to Proactive Investors.
Delhi, May 05, 2022: HempStreet, India's first research to retail venture in the medicinal cannabis sector, has announced partnership with European bio-pharma and phytocannabinoid company MGC Pharma.
LONDON, April 5, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines is pleased to announce that the Israeli Ministry of Health has approved the Dosing Study for CimetrA™ , MGC Pharma's proprietary treatment for the effects of COVID-19.
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) is currently undertaking a phase 3 clinical trial of CimetrA in Israel as an investigational medicinal product for the treatment of COVID-19 following successful phase 2 trials in 2020.